- Home
- CBIO vs DMII Comparison
CBIO vs DMII Comparison
Compare CBIO & DMII Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | CBIO | DMII |
|---|---|---|
| Founded | 2003 | 2024 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Blank Checks |
| Sector | | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 537.5M | 641.5M |
| IPO Year | 2013 | 2025 |
Fundamental Metrics
Financial Performance| Metric | CBIO | DMII |
|---|---|---|
| Price | $13.97 | $10.16 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $26.67 | N/A |
| AVG Volume (30 Days) | ★ 376.0K | 67.2K |
| Earning Date | 04-29-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $18,500.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $279.20 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.72 | $9.87 |
| 52 Week High | $27.41 | $10.33 |
Technical Indicators
Market Signals| Indicator | CBIO | DMII |
|---|---|---|
| Relative Strength Index (RSI) | 31.82 | 54.31 |
| Support Level | $9.95 | $10.12 |
| Resistance Level | $18.53 | $10.21 |
| Average True Range (ATR) | 1.41 | 0.02 |
| MACD | -0.63 | -0.00 |
| Stochastic Oscillator | 7.61 | 5.56 |
Price Performance
Historical ComparisonAbout CBIO Crescent Biopharma Inc.
Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent's pipeline product CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. The company focuses on advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.
About DMII Drugs Made In America Acquisition II Corp. Ordinary Shares
Drugs Made In America Acquisition II Corp is a blank check Company.